What happened to the modeling and simulation revolution?

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 4, 2014, Pages 416-417

  Bonate, P L ^a  

^a Pharmacokinetics Modeling and Simulation Astellas Pharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PHARMACOLOGY; COMMUNICATION SKILL; COMPARATIVE EFFECTIVENESS; DECISION MAKING; DRUG INDUSTRY; HUMAN; INTERVIEW; MATHEMATICAL MODEL; MEDICAL SOCIETY; PRIORITY JOURNAL; PROBABILITY; PUBLIC SPEAKING; PUBLISHING; REVIEW; SIMULATION; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG DEVELOPMENT; METABOLISM; PHARMACOKINETICS; PHARMACOLOGY;

DRUG;

COMPUTER SIMULATION; DRUG DISCOVERY; DRUG INDUSTRY; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 84921685466     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.123     Document Type: Review

References (5)

1. Lalonde, R. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007).
2. Milligan, P.A. et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin. Pharmacol. Ther. 93, 502-514 (2013).
3. Cook, J. Is model-based drug development delivering on its promise?: It depends on what the meaning of the word "is" is. American Conference on Pharmacometrics, Fort Lauderdale, FL, 12-15 May 2013.
4. Tornoe, C.W.; the ASCPT PMK Committee. PMX in submission: where are we now? Where should we go? American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, 18-22 March 2014.
5. Box, G.E.P. & Draper, N. Empirical Model-Building and Response Surfaces 424 (Wiley, New York, 1987).